Johns Hopkins AIDS Clinical Trials Unit

约翰霍普金斯大学是艾滋病临床研究的国家和国际领导者。拟议 约翰霍普金斯大学艾滋病临床试验单位（CTU）将汇集三个独立资助的艾滋病毒 进行（1）成人和（2）儿童治疗试验和（3）艾滋病毒预防的临床研究小组 research.这三个小组将组成一个统一的CTU，同时为三个DAIDS临床研究网络提供服务。 临床研究中心（CRS），位于东巴尔的摩的约翰霍普金斯医疗机构。该网站将 附属于拟议的（1）艾滋病临床试验组（ACTG）网络，（2）国际孕产妇 儿童青少年艾滋病临床试验（IMPAACT）网络，（3）艾滋病毒预防试验网络（HPTN）。 我们长期以来一直为DAIDS科学议程做出实质性贡献，特别是在以下领域： 预防和治疗试验，早期药物开发和实验治疗，神经病学， 肝炎病毒和艾滋病毒合并感染，以及儿科、青少年和母胎研究。调查人员 在这个提议的CTU中，撰写了1,000多篇与艾滋病毒感染有关的已发表论文，其中300多篇在 近五年同样的研究人员持有21个与艾滋病毒相关的NIH资助的赠款作为主要研究者 或共同主要研究者，每年直接费用超过7，000，000美元。我们现有的成人ACTG单位排名 第一次在全国范围内招募非洲裔美国人和妇女，其中许多人有实质性的历史 虐待数据管理被评为优秀，受试者保留是模范。CRS将从 这些附属诊所为3万多名艾滋病毒感染者和高危人群提供服务。这个新的反恐组将把 一大群有着良好合作历史的有成就的调查人员，并将允许整合 用于法规事务、数据管理、外展和招聘的行政资源。 在保留我们目前艾滋病毒临床试验结构的成功方面的同时，这次重组将 通过提供一个集中的、共享的管理核心，使机构受益， 这在约翰霍普金斯大学以前是不可能的。最重要的是，这三者的结合 这些团体将提供从出生到死亡的各个年龄段的艾滋病毒预防和治疗研究。 青春期到成年期和衰老期。反恐组有能力继续进行广泛而实质性的 为国家和国际艾滋病毒临床研究做出贡献，同时也为社区服务。

The Johns Hopkins University is a national and international leader in HIV clinical research. The proposed Johns Hopkins University AIDS Clinical Trials Unit (CTU) will bring together three independently funded HIV clinical research groups that perform (1) adult and (2) pediatric treatment trials, and (3) HIV prevention research. These three groups will form a unified CTU serving three DAIDS clinical research networks at one Clinical Research Site (CRS), The Johns Hopkins Medical Institutions in East Baltimore. The Site will be affiliated with the proposed (1) AIDS Clinical Trials Group (ACTG) Network, (2) International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, (3) HIV Prevention Trials Network (HPTN). We have a long history of substantive contribution to the DAIDS scientific agenda, especially in the areas of prevention and treatment trials, early phase drug development and experimental therapeutics, neurology, hepatitis virus and HIV co-infection, and pediatric, adolescent, and maternal-fetal research. The investigators in this proposed CTU have authored over 1,000 published papers related to HIV infection, >300 of these in the past five years. The same investigators hold 21 HIV-related NIH-funded grants as Principal Investigator or Co-Principal Investigator for over $7,000,000 in annual direct costs. Our existing Adult ACTG Unit ranks first nationally in recruitment of African-Americans and women, many of whom have a history of substance abuse. Data management is rated outstanding, and subject retention is exemplary. The CRS will recruit from affiliated clinics serving more than 30,000 HIV-infected and at-risk persons. This new CTU will bring together a large group of accomplished investigators with a strong history of collaboration, and will allow consolidation of administrative resources for regulatory affairs, data management, outreach, and recruitment. While preserving the successful aspects of our current HIV clinical trials structure, this reorganization will benefit the institution by providing a centralized, shared administrative core, which will allow an economyof scale that has not previously been possible at Johns Hopkins. Above all, the joining together of these three groups will provide access to HIV prevention and treatment research across the age spectrum, from birth to adolescence to adulthood and senescence. This CTU is well-positioned to continue its broad and substantial contributions to national and international HIV clinical research, while also serving its community.